Shots:

• Thermo Fischer signs a 3yrs. collaboration with Genome Canada and the Ontario Institute for Cancer Research (OICR) to develop targeted next-generation sequencing-based assays and analysis software for $6M. Genome to fund $2M for development & validation which will split b/w Thermo Fischer and OICR
•  The partners will develop one assay for diagnosis of pancreatic cancer and two for prostate & breast cancer. Additionally- the assays will be used to stratify patients in clinical trials in Ontario and other jurisdictions following the previous collaboration of OICR and Thermo Fisher  
• The NGS assays DNA & gene expression signatures from RNA providing an insight into cancer driver mutations. The collaboration will bring Thermo Fisher's Ion Torrent technology across Canada  

Click here to­ read full press release/ article | Ref: Thermo Fisher| Image: Twitter